Quantification of cerebral A1 adenosine receptors in humans using [18F]CPFPX and PET: an equilibrium approach
暂无分享,去创建一个
Karl Zilles | Andreas Bauer | Marcus H. Holschbach | David Elmenhorst | Philipp T. Meyer | Andreas Matusch | Heinz H. Coenen | Dirk Bier | K. Zilles | P. Meyer | H. Coenen | A. Bauer | D. Elmenhorst | A. Matusch | D. Bier | M. Holschbach
[1] W C Eckelman,et al. Kinetic Modeling of [11C]Raclopride: Combined PET-Microdialysis Studies , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[2] Christer Halldin,et al. PET Studies of Binding Competition between Endogenous Dopamine and the D1 Radiotracer [11C]NNC 756 , 1998, NeuroImage.
[3] R Joeres,et al. Influence of smoking on caffeine elimination in healthy volunteers and in patients with alcoholic liver cirrhosis , 1988, Hepatology.
[4] John W. Daly,et al. Chronic Effects of Xanthines on Levels of Central Receptors in Mice , 1999, Cellular and Molecular Neurobiology.
[5] Christian Boy,et al. Quantification of Cerebral A1 Adenosine Receptors in Humans using [18F]CPFPX and PET , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[6] S. Rössner,et al. Removal of exogenous triglycerides in human forearm muscle and subcutaneous tissue. , 2009, Acta medica Scandinavica.
[7] C. Cotman,et al. Reduced density of adenosine A1 receptors and preserved coupling of adenosine A1 receptors to G proteins in alzheimer hippocampus: A quantitative autoradiographic study , 1993, Neuroscience.
[8] R. Lewis,et al. A1 adenosine receptor antagonists as ligands for positron emission tomography (PET) and single-photon emission tomography (SPET). , 1998, Journal of medicinal chemistry.
[9] P B Hoffer,et al. In vivo quantification of dopamine D2 receptor parameters in nonhuman primates with [123I]iodobenzofuran and single photon emission computerized tomography. , 1994, European journal of pharmacology.
[10] U Pietrzyk,et al. An interactive technique for three-dimensional image registration: validation for PET, SPECT, MRI and CT brain studies. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[11] Dirk Bier,et al. Synthesis and evaluation of no-carrier-added 8-cyclopentyl-3-(3-[(18)F]fluoropropyl)-1-propylxanthine ([(18)F]CPFPX): a potent and selective A(1)-adenosine receptor antagonist for in vivo imaging. , 2002, Journal of medicinal chemistry.
[12] D L Alexoff,et al. A Strategy for Removing the Bias in the Graphical Analysis Method , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[13] U. Fuhr,et al. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. , 1999, Pharmacogenetics.
[14] S. Haber,et al. Imaging Human Mesolimbic Dopamine Transmission with Positron Emission Tomography. Part II: Amphetamine-Induced Dopamine Release in the Functional Subdivisions of the Striatum , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[15] D. Charney,et al. PET quantification of 5-HT2A receptors in the human brain: a constant infusion paradigm with [18F]altanserin. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[16] Doris J. Doudet,et al. In Vivo Receptor Assay with Multiple Ligand Concentrations: An Equilibrium Approach , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[17] F. Berthou,et al. Caffeine increases its own metabolism through cytochrome P4501A induction in rats. , 1995, Life sciences.
[18] W C Eckelman,et al. Quantification of Amphetamine-Induced Changes in [11C]Raclopride Binding with Continuous Infusion , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[19] Horst Halling,et al. Evaluation of 18F-CPFPX, a novel adenosine A1 receptor ligand: in vitro autoradiography and high-resolution small animal PET. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[20] T. Porkka-Heiskanen,et al. Adenosine and sleep. , 2002, Sleep medicine reviews.
[21] R. Faull,et al. Loss of A1 adenosine receptors in human temporal lobe epilepsy , 1996, Brain Research.
[22] P B Hoffer,et al. Single photon emission tomography measurement of benzodiazepine receptor number and affinity in primate brain: a constant infusion paradigm with [123I]iomazenil. , 1993, European journal of pharmacology.
[23] C. Alm,et al. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. , 2000, Therapeutic drug monitoring.
[24] P B Hoffer,et al. Microdialysis and SPECT measurements of amphetamine‐induced dopamine release in nonhuman primates , 1997, Synapse.
[25] Robert B. Innis,et al. Kinetic and equilibrium analyses of [123I]epidepride binding to striatal and extrastriatal dopamine D2 receptors , 1999 .
[26] J. Fritschy,et al. Seizure Suppression by Adenosine A1 Receptor Activation in a Mouse Model of Pharmacoresistant Epilepsy , 2003, Epilepsia.
[27] G Blomqvist,et al. Comparison of the Transient Equilibrium and Continuous Infusion Method for Quantitative PET Analysis of [11C]Raclopride Binding , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[28] David J. Schlyer,et al. Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[29] R. Cunha,et al. Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors , 2001, Neurochemistry International.
[30] D E Kuhl,et al. Equilibrium versus Compartmental Analysis for Assessment of the Vesicular Monoamine Transporter Using (+)-α-[11C]Dihydrotetrabenazine (DTBZ) and Positron Emission Tomography , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[31] V. Ramkumar,et al. Adenosine, oxidative stress and cytoprotection. , 2001, Japanese journal of pharmacology.
[32] R. Carson,et al. PET physiological measurements using constant infusion. , 2000, Nuclear medicine and biology.
[33] Lutz Tellmann,et al. In vivo imaging of rat brain A1 adenosine receptor occupancy by caffeine , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[34] Gilles Tamagnan,et al. Influence of acetylcholine levels on the binding of a SPECT nicotinic acetylcholine receptor ligand [123I]5‐I‐A‐85380 , 2003, Synapse.
[35] Gerhard Ransmayr,et al. Loss of human hippocampal adenosine A1 receptors in dementia: evidence for lack of specificity , 1998, Neuroscience Letters.
[36] R Kawashima,et al. Cerebral blood flow measurement with iodine-123-IMP SPECT, calibrated standard input function and venous blood sampling. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[37] J. A. Carrillo,et al. Clinically Significant Pharmacokinetic Interactions Between Dietary Caffeine and Medications , 2000, Clinical pharmacokinetics.
[38] Chang-Shin Park,et al. Effect of age and smoking on in vivo CYP1A2, flavin‐containing monooxygenase, and xanthine oxidase activities in Koreans: Determination by caffeine metabolism , 2000, Clinical pharmacology and therapeutics.
[39] M Slifstein,et al. Effects of statistical noise on graphic analysis of PET neuroreceptor studies. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[40] W C Eckelman,et al. Measurement of dopamine release with continuous infusion of [11C]raclopride: optimization and signal-to-noise considerations. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[41] H G Mandel,et al. Update on caffeine consumption, disposition and action. , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[42] D. Charney,et al. Spect imaging of striatal dopamine release after amphetamine challenge in humans: Relationship between subjective effects and dopamine release , 1995, Schizophrenia Research.
[43] J W Jefferson,et al. Drug and diet interactions: avoiding therapeutic paralysis. , 1998, The Journal of clinical psychiatry.
[44] Karl Zilles,et al. In vivo imaging of adenosine A1 receptors in the human brain with [18F]CPFPX and positron emission tomography , 2003, NeuroImage.
[45] Claus Svarer,et al. Quantification of 5-HT2A Receptors in the Human Brain Using [18F]Altanserin-PET and the Bolus/Infusion Approach , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[46] Roger N Gunn,et al. A bolus/infusion paradigm for the novel NMDA receptor SPET tracer [123I]CNS 1261. , 2004, Nuclear medicine and biology.
[47] C Burger,et al. Requirements and implementation of a flexible kinetic modeling tool. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[48] Peter Herscovitch,et al. Comparison of Bolus and Infusion Methods for Receptor Quantitation: Application to [18F]Cyclofoxy and Positron Emission Tomography , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[49] Elizabeth Landrum Michalets,et al. Update: Clinically Significant Cytochrome P‐450 Drug Interactions , 1998, Pharmacotherapy.
[50] Anne Constable,et al. The effects of coffee on enzymes involved in metabolism of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in rats. , 2003, Chemico-biological interactions.
[51] M. Mintun,et al. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.
[52] Robert B. Innis,et al. SPECT Quantification of [123I]Iomazenil Binding to Benzodiazepine Receptors in Nonhuman Primates: II. Equilibrium Analysis of Constant Infusion Experiments and Correlation with in vitro Parameters , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[53] T. Dunwiddie,et al. The Role and Regulation of Adenosine in the Central Nervous System , 2022 .
[54] J. Seibyl,et al. SPECT measurement of benzodiazepine receptors in human brain with iodine-123-iomazenil: kinetic and equilibrium paradigms. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[55] M Fujita,et al. Imaging extrastriatal dopamine D(2) receptor occupancy by endogenous dopamine in healthy humans. , 2000, European journal of pharmacology.
[56] Helmut L. Haas,et al. Functions of neuronal adenosine receptors , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.